Marta Miarons

Ayuda Buscar en la ayuda Buscar en la ayuda Influencia de los polimorfismos del gen UGT1A1 en el tratamiento con sacituzumab govitecan: revisión narrativa Eva María Legido Perdices [1] ; Fernando do Pazo Oubiña [2] ; Elena Prado Mel [3] ; Marta Miarons [4] ; Betel Del Rosario García [5] ; Fernando Gutiérrez Nicolás [5] [1] Hospital Arnau de Vilanova-Llíria, Valencia, España [2] Hospital Universitario Son Espases, Palma, España [3] Hospital Universitario Virgen del Rocío, Sevilla, España [4]...

Pharmaceutical interventions in the emergency department: cost-effectiveness and cost-benefit analysis http://orcid.org/0000-0001-7847-1580Marta Miarons1,2, Sergio Marín2,3, Imma Amenós4, Lluis Campins2, Montse Rovira4, Manuel Daza4 1 Pharmacy Department, Vall d'Hebron Hospital, Barcelona, Catalunya, Spain 2 Pharmacy Department, Mataro Hospital, Barcelona, Spain 3 Pharmacy Department, Hospital Germans Trias i Pujol, Badalona, Catalunya, Spain 4 Emergency Department, Mataro Hospital, Mataro,...

Abstract What is known and objective Tocilizumab is an IL‐6 receptor inhibitor agent which has been proposed as a candidate to stop the inflammatory phase of infection by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). However, safety data of tocilizumab in pregnant women and their newborn are scarce. We aimed to describe maternal and neonatal safety outcomes associated with tocilizumab treatment in pregnant women with severe COVID‐19.